Evidence map›Paper›PMID 38886900›Full record

ArticleClinical and translational medicine2024

Deletion of endothelial IGFBP5 protects against ischaemic hindlimb injury by promoting angiogenesis.

Fei Song, Yu Hu, Yi-Xiang Hong, Hu Sun, Yue Han, Yi-Jie Mao, Wei-Yin Wu, Gang Li, Yan Wang

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. METTL14-dependent NExperimental & molecular medicine · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. The blood-brain barrier: a help and a hindrance.Brain : a journal of neurology · 2025
    Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fei SongXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yu HuXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.ORCID 0009-0002-7180-5378
Yi-Xiang HongXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Hu SunXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yue HanXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yi-Jie MaoXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Wei-Yin WuXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Gang LiXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.ORCID 0000-0003-3875-2112
Yan WangXiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

Funding

National Natural Science Foundation of China 81900336National Natural Science Foundation of China 82270417
6 · The paper itself

Abstract

backgroundAngiogenesis is critical for forming new blood vessels from antedating vascular vessels. The endothelium is essential for angiogenesis, vascular remodelling and minimisation of functional deficits following ischaemia. The insulin-like growth factor (IGF) family is crucial for angiogenesis. Insulin-like growth factor-binding protein 5 (IGFBP5), a binding protein of the IGF family, may have places in angiogenesis, but the mechanisms are not yet completely understood. We sought to probe whether IGFBP5 is involved in pathological angiogenesis and uncover the molecular mechanisms behind it. METHODS AND

resultsIGFBP5 expression was elevated in the vascular endothelium of gastrocnemius muscle from critical limb ischaemia patients and hindlimb ischaemic (HLI) mice and hypoxic human umbilical vein endothelial cells (HUVECs). In vivo, loss of endothelial IGFBP5 (IGFBP5

conclusionOur findings demonstrate that IGFBP5 ablation enhances angiogenesis by promoting ATP metabolism and stabilising HIF1α, implying IGFBP5 is a novel therapeutic target for treating abnormal angiogenesis-related conditions.

Indexed as

HindlimbInsulin-Like Growth Factor Binding Protein 5AngiogenesisAnimalsDisease Models, AnimalHumansHuman Umbilical Vein Endothelial CellsIschemiaMaleMiceNeovascularization, PhysiologicIGFBP5 protein, humanInsulin-Like Growth Factor Binding Protein 5angiogenesiscell proliferationIGF1/IGF2IGF1RIGFBP5

Identifiers

PMID38886900
PMCPMC11182737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.